Key facts
- Protelight Pharmaceuticals’s last known valuation is $351.9M (Nov 2025).
- It has raised $115.0M; the latest was IPO in Feb 2026.
- Notable investors include Shenzhen Yifeng Investment Management Enterprise, Infinity Group, Wuxi Guolian Development (Group), Cherami Investment Group, Qingdao Conson Financial Holdings — 12 tracked in total.
- Status: In IPO Registration.
Investors
12+- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Protelight Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Protelight Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Protelight Pharmaceuticals
Developer and manufacturer of novel antimicrobial peptide drugs and therapeutic candidates designed for drug-resistant infections, metabolic disorders, and autoimmune diseases. The company provides innovative peptide therapies and proprietary technology platforms, enabling patients and healthcare providers with new treatment mechanisms, improved efficacy, and solutions for unmet clinical needs.
- Sector
- Healthcare
- HQ
- Jiangyin, China
- Founded
- 2009
- Employees
- 109
- Website
- protelight.com/
- Ownership
- In IPO Registration
Protelight Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Protelight Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Protelight Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.